Elizabeth Logers, MD, PhD, discusses the implications of ovarian toxicity on female patients of reproductive age being treated with nirogacestat for desmoid tumors.
Elizabeth Loggers, MD, PhD
Advertisement
Elizabeth Loggers, MD, PhD, is an associate professor in the Clinical Research Division at Fred Hutch Cancer Center.
Articles by Elizabeth Loggers, MD, PhD
Elizabeth Loggers, MD, PhD, medical oncologist, Seattle Cancer Care Alliance, discusses the role that she expects immunotherapy will play in the future treatment landscape of sarcoma.
Advertisement
Latest Updated Articles
Nirogacestat Shows Promise With Manageable Fertility Concerns in Young WomenPublished: June 22nd 2024 | Updated:
The Role of Immunotherapy in the Future Treatment Landscape of SarcomaPublished: November 12th 2016 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
3
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
4
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
5
